- Markets
- Healthcare
- TRABI
TRABI
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Transgene Biotek Approves Funding Proposal To Raise Funds On Securitized Basis
Jan 24 (Reuters) - Transgene Biotek Ltd TRBL.BO:
APPROVES FUNDING PROPOSAL TO RAISE FUNDS ON SECURITIZED BASIS
Source text: ID:nBSE6pq92F
Further company coverage: TRBL.BO
(([email protected];;))
Jan 24 (Reuters) - Transgene Biotek Ltd TRBL.BO:
APPROVES FUNDING PROPOSAL TO RAISE FUNDS ON SECURITIZED BASIS
Source text: ID:nBSE6pq92F
Further company coverage: TRBL.BO
(([email protected];;))
Events:
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Transgene Biotek do?
Transgene Biotek Ltd specializes in manufacturing drugs including New Drug Delivery Systems, Biogenerics, Human Vaccines, and Cancer Drugs/Oncology. They also offer services in Diagnostics and CRO.
Who are the competitors of Transgene Biotek?
Transgene Biotek major competitors are KK Shah Hospitals, Nidan Labs. & Health, Family Care Hospital, Sharma Hospitals, Chennai Meena Multi, Soni Medicare, Global Longlife Hosp. Market Cap of Transgene Biotek is ₹30 Crs. While the median market cap of its peers are ₹26 Crs.
Is Transgene Biotek financially stable compared to its competitors?
Transgene Biotek seems to be less financially stable compared to its competitors. Altman Z score of Transgene Biotek is -0.61 and is ranked 8 out of its 8 competitors.
Does Transgene Biotek pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Transgene Biotek latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Transgene Biotek allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Transgene Biotek balance sheet?
Transgene Biotek balance sheet is weak and might have solvency issues
Is the profitablity of Transgene Biotek improving?
Yes, profit is increasing. The profit of Transgene Biotek is -₹0.66 Crs for Mar 2024, -₹6.01 Crs for Mar 2023 and -₹10.4 Crs for Mar 2022
Is the debt of Transgene Biotek increasing or decreasing?
The debt of Transgene Biotek is decreasing. Latest debt of Transgene Biotek is ₹13.95 Crs as of Sep-24. This is less than Mar-24 when it was ₹13.99 Crs.
Is Transgene Biotek stock expensive?
There is insufficient historical data to gauge this. Latest PE of Transgene Biotek is 0
Has the share price of Transgene Biotek grown faster than its competition?
Transgene Biotek has given lower returns compared to its competitors. Transgene Biotek has grown at ~-47.02% over the last 1yrs while peers have grown at a median rate of -26.0%
Is the promoter bullish about Transgene Biotek?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Transgene Biotek is 23.64% and last quarter promoter holding is 23.64%.
Are mutual funds buying/selling Transgene Biotek?
There is Insufficient data to gauge this.